Avelumab and Merkel Cell Carcinoma: Examining the Evidence for Causation

Legacy Context: General Health and Science Information

The legacy theme of general health and science information has historically served as a foundation for public understanding of broad medical topics, including cancer biology and therapeutic interventions. Within this context, discussions of drug safety and adverse effects have typically centered on common, well-documented risks. Transitioning to a more specialized domain, the focus narrows to specific pharmaceutical agents and their potential causal relationships with rare diseases. In the mass production setting, occupational exposure to biologics such as Avelumab—a monoclonal antibody used in oncology—raises distinct concerns. While Avelumab is indicated for the treatment of Merkel Cell Carcinoma, the question of whether it can cause this malignancy represents a pivot from therapeutic benefit to occupational hazard. This shift requires examining exposure pathways distinct from patient administration, including inhalation or dermal contact during manufacturing. The bridge concept thus moves from general health literacy to a targeted inquiry: assessing the risk of Merkel Cell Carcinoma among workers handling Avelumab, without invoking mechanistic disease claims. This transition underscores the need for rigorous exposure monitoring and epidemiological surveillance in industrial environments.

Bridge Transition: From General Safety to Specific Causation Inquiry

Building on the legacy framework, we now focus specifically on Avelumab and its potential to cause Merkel Cell Carcinoma (MCC). Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial, JAVELIN Merkel 200, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The question of causation is critical for both patients and workers exposed to Avelumab.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease presents as a firm, painless, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, which reveal neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). MCC is associated with high rates of recurrence and mortality, and despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Avelumab Pharmacology and Reported Adverse Effects

Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can include a range of inflammatory conditions, such as pneumonitis, colitis, hepatitis, endocrinopathies, and dermatologic reactions. A reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). The spectrum of irAEs underscores the need for careful monitoring during treatment.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The query asks whether avelumab causes MCC. The evidence does not support a causal relationship in which avelumab induces or initiates the development of MCC. Instead, avelumab is a treatment for MCC. The mechanistic pathway is the opposite: avelumab targets PD-L1 to treat existing MCC. Immune checkpoint inhibition, including with avelumab, has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, a subset of patients becomes refractory to avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in this setting (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Thus, the link between avelumab and MCC is therapeutic, not causative.

Adequacy of Warnings and Causation-Related Considerations

Given that avelumab is approved specifically for the treatment of metastatic MCC, warnings appropriately focus on its use in this patient population. The evidence does not indicate that avelumab causes MCC; rather, it is indicated for MCC. Therefore, warnings about MCC as an adverse effect would be clinically irrelevant and potentially misleading. The evidence does not suggest any inadequacy in warnings regarding avelumab and MCC causation, as no such causation exists. For patients with MCC, the primary causation consideration is the underlying disease, not avelumab. MCC is associated with ultraviolet light exposure and Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab is used to treat MCC, and its benefits—durable responses and significant clinical benefit—outweigh risks for many patients (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, patients who progress on avelumab face a poor prognosis, and alternative treatments like ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Causation-related considerations should focus on the natural history of MCC and the efficacy of avelumab, rather than on avelumab as a cause of MCC.

Timeline Between Exposure and Documented Harm

The timeline between avelumab exposure and harm is relevant to irAEs, not to MCC development. For example, hypercalcemia due to sarcoidosis reactivation occurred during avelumab treatment for metastatic MCC and was managed without discontinuing therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that harm (disease progression) occurs in a majority of patients despite treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The evidence does not document a timeline in which avelumab exposure leads to the development of MCC; instead, MCC is present before avelumab is administered.

Conclusion

The evidence does not support the assertion that avelumab causes Merkel cell carcinoma. Avelumab is a therapeutic agent approved for the treatment of metastatic MCC, and its use is associated with immune-related adverse events but not with the induction of MCC. The relationship between avelumab and MCC is one of treatment, not causation. Patients and clinicians should be aware of the risks of irAEs and the possibility of disease progression, but not of avelumab as a cause of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, the evidence does not support that Avelumab causes Merkel Cell Carcinoma (MCC). Avelumab is a treatment for MCC, not a cause. It is a monoclonal antibody that targets PD-L1 to treat existing MCC. The known causes of MCC include ultraviolet light exposure and Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What are the adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis, endocrinopathies, and dermatologic reactions (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are due to overactivation of the immune system and require careful monitoring.

Is there a risk of Merkel Cell Carcinoma from occupational exposure to Avelumab?

There is no evidence that Avelumab causes MCC, even with occupational exposure. The drug is designed to treat MCC, and its mechanism of action does not involve inducing cancer. However, occupational exposure to biologics should be minimized as a general safety practice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.